Physician profile
Adolph William Johnson
NPI 1235139387
$10,746.28
in general payments reported to CMS, 2019-2025
47 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $1,588 · 2021: $2,131 · 2022: $1,871 · 2023: $1,869 · 2024: $1,012 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,604.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,150.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,144.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $905.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $819.49 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $710.35 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $622.09 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $567.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $477.05 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amarin Pharma, INC. | $391.31 | 2019-2023 | |
| Horizon Therapeutics Plc | $388.62 | 2019-2023 | Krystexxa |
| Astellas Pharma US INC | $360.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $335.61 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.47 | 2019-2024 | Xifaxan, Cycloset |
| Kowa Pharmaceuticals America, INC. | $230.26 | 2019-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $195.94 | 2023-2025 | Gemtesa |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolph Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.